Sulfaguanidine: Difference between revisions

Browse history interactively← Previous editContent deleted Content addedVisual Wikitext

Revision as of 23:12, 30 June 2011 editCheMoBot (talk \| contribs)Bots141,565 edits Updating {{drugbox}} (changes to verified fields - updated 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEMBL_Ref') per Chem/Drugbox validation (report [[Misplaced Pages talk:WikiProject_Ph← Previous edit		Latest revision as of 15:39, 8 October 2024 edit undoJWBE (talk \| contribs)Extended confirmed users10,126 edits added Category:4-Aminophenyl compounds using HotCat
(29 intermediate revisions by 23 users not shown)
Line 1:		Line 1:
			{{Short description\|Chemical compound}}
	{{drugbox
			{{refimprove\|date=August 2021}}
	\| Verifiedfields = changed
			{{Drugbox
	\| UNII_Ref = {{fdacite\|changed\|FDA}}
			\| Watchedfields = changed
			\| verifiedrevid = 437133996
			\| IUPAC_name = 4-Amino-''N''-benzenesulfonamide
			\| image = Sulfaguanidin.svg
			<!--Clinical data-->
			\| tradename =
			\| Drugs.com = {{drugs.com\|international\|sulfaguanidine}}
			\| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
			\| pregnancy_US = <!-- A / B / C / D / X -->
			\| pregnancy_category =
			\| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
			\| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
			\| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
			\| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
			\| legal_status =
			\| routes_of_administration =
			<!--Pharmacokinetic data-->
			\| bioavailability =
			\| protein_bound =
			\| metabolism =
			\| elimination_half-life =
			\| excretion =
			<!--Identifiers-->
			\| CAS_number = 57-67-0
			\| ATC_prefix = A07
			\| ATC_suffix = AB03
			\| PubChem = 5324
			\| DrugBank_Ref = {{drugbankcite\|correct\|drugbank}}
			\| DrugBank =
			\| UNII_Ref = {{fdacite\|correct\|FDA}}
	\| UNII = 15XQ8043FN		\| UNII = 15XQ8043FN
	\| verifiedrevid = 408901519
	\| IUPAC_name = 4-amino-''N''-benzenesulfonamide
	\| image = sulfaguanidine.png
	\| CAS_number = 57-67-0
	\| CASNo_Ref = {{cascite}}
	\| ATC_prefix = A07
	\| ATC_suffix = AB03
	\| PubChem = 5324
	\| DrugBank =
	\| KEGG_Ref = {{keggcite\|correct\|kegg}}		\| KEGG_Ref = {{keggcite\|correct\|kegg}}
	\| KEGG = D02437		\| KEGG = D02437
			\| ChemSpiderID = 5133
	\| C=7\|H=10\|N=4\|O=2\|S=1
			\| smiles = c1cc(N)ccc1S(=O)(=O)N=C(N)N
	\| molecular_weight = 214.2449 g/mol
			\| StdInChI = 1S/C7H10N4O2S/c8-5-1-3-6(4-2-5)14(12,13)11-7(9)10/h1-4H,8H2,(H4,9,10,11)
	\| bioavailability =
			\| StdInChIKey = BRBKOPJOKNSWSG-UHFFFAOYSA-N
	\| protein_bound =
			<!--Chemical data-->
	\| metabolism =
			\| C=7 \| H=10 \| N=4 \| O=2 \| S=1
	\| elimination_half-life =
			\| melting_point = 190
	\| excretion =
			\| melting_high = 193
	\| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
	\| pregnancy_US = <!-- A / B / C / D / X -->
	\| pregnancy_category=
	\| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
	\| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
	\| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
	\| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
	\| legal_status =
	\| routes_of_administration =
	}}		}}

	'''Sulfaguanidine''' is a ].		'''Sulfaguanidine''' is a ].

			Sulfaguanidine is a ] derivative of ] used in veterinary medicine. Sulfaguanidine is poorly absorbed from the gut which makes it suitable for the treatment of ] and other ] infections.<ref>{{cite journal \| vauthors = Smyth CJ, Finkelstein MB, Gould SE, Koppa TM, Leeder FS \| title = Acute Bacillary Dysentery (Flexner): Treatment with Sulfaguanidine and Succinylsulfathiazole \| journal = Journal of the American Medical Association \| date = April 1943 \| volume = 121 \| issue = 17 \| pages = 1325–30 \| doi = 10.1001/jama.1943.02840170009003 }}</ref>

			Sulphaguanidine (II) was independently prepared by Marshall, Bratton, White, and Litchfield and Roblin, Williams, Winnek, and English in 1940, and introduced for the treatment of bacillary dysentery on the basis of its poor absorption from the gut. Its orally administered route of administration is now well established.<ref>{{cite journal \| vauthors = Rose FL, Spinks A \| title = The absorption of some sulphaguanidine derivatives in mice \| journal = British Journal of Pharmacology and Chemotherapy \| volume = 2 \| issue = 2 \| pages = 65–78 \| date = June 1947 \| pmid = 19108113 \| pmc = 1509772 \| doi = 10.1111/j.1476-5381.1947.tb00322.x }}</ref>

			== References ==
			{{Reflist}}

	{{Antidiarrheals, intestinal anti-inflammatory/anti-infective agents}}		{{Antidiarrheals, intestinal anti-inflammatory/anti-infective agents}}
Line 40:		Line 58:
	]		]
	]		]
			]

	General
	Synonyms: sulfaguanidine, 4-amino-N-(aminoiminomethyl)benzenesulfonamide, 4-amino-N-guanylbenzenesulfonamide, abiguanil, aterian, ganidan, guamide, guanicil, guanidan, resulfon, ruocid, shigatix, suganyl, sulfoguanidine, sulfoguenil, sulgin
	Use: veterinary drug
	Molecular formula: C7H10N4O2S
	CAS No: 57-67-0
	EINECS No: 200-345-9
	Physical data
	Appearance: white powder
	Melting point:
	Boiling point:
	Vapour density:
	Vapour pressure:
	Density (g cm-3):
	Flash point:
	Explosion limits:
	Autoignition temperature:
	Water solubility:

	Stability
	Stable. Incompatible with strong oxidizing agents.

	Toxicology
	Eye, respiratory and skin irritant. May be harmful - toxicology not fully investigated..
	Toxicity data
	(The meaning of any toxicological abbreviations which appear in this section is given here.)


	Risk phrases
	(The meaning of any risk phrases which appear in this section is given here.)
	R36 R37 R38.


	Transport information
	(The meaning of any UN hazard codes which appear in this section is given here.)
	Non-hazardous for air, sea and road freight.
	Personal protection
	Safety glasses, adequate ventilation.
	Safety phrases
	(The meaning of any safety phrases which appear in this section is given here.)
	S26 S36.


	{{gastrointestinal-drug-stub}}		{{gastrointestinal-drug-stub}}

	]
	]
	]
	]